Literature DB >> 25424817

Relationship of immunogenicity to protective potency in acellular pertussis vaccines.

Dorothy Xing1, Catpagavalli Asokanathan, Ying Hua Xu, Barbara Bolgiano, Alex Douglas-Bardsley, Shumin Zhang, Junzhi Wang, Michael Corbel.   

Abstract

Comparison of the immunogenicity response and resistance to challenge in the modified intracerebral challenge assay induced by various acellular pertussis vaccines showed that these were not closely linked. The immunogenicity assay was effective for confirming the presence of specific antigenic components and was invaluable for detecting minor components present in co-purified vaccines. However, the magnitude of antibody responses was not consistently related to antigen concentration nor did it correlate with protection in the modified intracerebral challenge assay. The immunogenicity assay detected degradation of pertussis toxin and pertactin components but not of filamentous haemagglutinin or fimbriae 2 and 3 in denatured acellular pertussis vaccines. The modified intracerebral challenge assay was effective in detecting antigen degradation in all types of acellular pertussis vaccines including those of European/North American origin but was dominated by the response to pertussis toxin. Aerosol challenge was more sensitive in detecting denaturation of filamentous haemagglutinin or fimbriae. The modified intracerebral challenge assay was the only assay that provided a quantitative indication of protective activity. Both immunogenicity and challenge assays provided useful data on acellular pertussis vaccine properties but were complementary and not alternatives.

Keywords:  acellular pertussis vaccines; aerosol challenge model; immunogenicity assay; modified Kendrick test; potency assays

Mesh:

Substances:

Year:  2014        PMID: 25424817      PMCID: PMC4186029          DOI: 10.4161/hv.28765

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  26 in total

1.  VACCINATION against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley.

Authors: 
Journal:  Br Med J       Date:  1956-08-25

2.  Why do pertussis vaccines fail?

Authors:  James D Cherry
Journal:  Pediatrics       Date:  2012-04-23       Impact factor: 7.124

3.  Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.

Authors:  R Gaines-Das; Y Horiuchi; S M Zhang; P Newland; Y Kim; M Corbel; D Xing
Journal:  Vaccine       Date:  2009-09-16       Impact factor: 3.641

4.  Pertussis cases rise 10-fold among older children and adults in England and Wales.

Authors:  Zosia Kmietowicz
Journal:  BMJ       Date:  2012-07-23

Review 5.  Immunity to the respiratory pathogen Bordetella pertussis.

Authors:  R Higgs; S C Higgins; P J Ross; K H G Mills
Journal:  Mucosal Immunol       Date:  2012-06-20       Impact factor: 7.313

6.  Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

Authors:  Maxwell A Witt; Larry Arias; Paul H Katz; Elizabeth T Truong; David J Witt
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.

Authors:  Elinor Reynolds; Barry Walker; Dorothy Xing; Joanna Southern; Catpagavalli Asokanathan; Belinda Dagg; Michael Corbel; Elizabeth Miller
Journal:  Vaccine       Date:  2006-01-25       Impact factor: 3.641

8.  Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model.

Authors:  K H Mills; A Barnard; J Watkins; K Redhead
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

9.  A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

Authors:  K H Mills; M Ryan; E Ryan; B P Mahon
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

10.  Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Authors:  Pádraig J Ross; Caroline E Sutton; Sarah Higgins; Aideen C Allen; Kevin Walsh; Alicja Misiak; Ed C Lavelle; Rachel M McLoughlin; Kingston H G Mills
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more
  3 in total

Review 1.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

Review 2.  Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Authors:  Kevin Markey; Catpagavalli Asokanathan; Ian Feavers
Journal:  Toxins (Basel)       Date:  2019-07-17       Impact factor: 4.546

Review 3.  Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative.

Authors:  Ye Feng; Cheng-Hsun Chiu; Ulrich Heininger; Daniela Flavia Hozbor; Tina Quanbee Tan; Carl-Heinz Wirsing von König
Journal:  Lancet Reg Health West Pac       Date:  2021-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.